Department of Internal Medicine, Section of Pharmacology, Vascular and Metabolic Disease, Erasmus Medical Centre, Rotterdam, The Netherlands.
Curr Opin Pharmacol. 2011 Apr;11(2):162-74. doi: 10.1016/j.coph.2011.01.002. Epub 2011 Feb 4.
The current concept is that there are both cells that integrate into the vasculature, true endothelial progenitor cells (EPC), and cells with hematopoietic markers that support neovascularisation. As identification of the EPC is controversial and studies refer cells that might fall into either pools, we will use the term, vasculogenesis-related progenitor cells (VRPC), for this review. VRPC are considered to be an important target for the treatment of cardiovascular diseases (CVD). Angiotensin II is known to be an important player in neovascularisation and the modulation of renin angiotensin system (RAS) is one of the major pharmacotherapeutic strategies for the treatment of CVD. We will review the effects of different components of the RAS on such VRPC under physiological conditions and in CVD. The reviewed research strongly supports a critical role of the RAS in vasculogenesis and vascular regeneration. Therefore, pharmacological intervention on the components of the RAS does not only target directly end-organ remodelling and blood pressure but also influence tissue healing and/or regeneration by influencing specific progenitor cells. Thus, the interrogation of RAS effects on VRPC will be important in the optimisation of RAS intervention or regenerative therapy.
目前的概念是，既有整合到脉管系统中的细胞，即真正的内皮祖细胞 (EPC)，也有具有造血标志物的细胞，它们支持新血管生成。由于 EPC 的鉴定存在争议，并且研究中提到的细胞可能属于两个池中的任何一个，因此我们将在本综述中使用“血管生成相关祖细胞 (VRPC)”这一术语。VRPC 被认为是治疗心血管疾病 (CVD) 的重要靶点。血管紧张素 II 已知是新血管生成的重要参与者，而肾素血管紧张素系统 (RAS) 的调节是 CVD 治疗的主要药物治疗策略之一。我们将回顾 RAS 的不同成分在生理条件下和 CVD 中对这种 VRPC 的影响。综述研究强烈支持 RAS 在血管生成和血管再生中的关键作用。因此，RAS 成分的药理学干预不仅直接针对终末器官重塑和血压，而且还通过影响特定的祖细胞来影响组织愈合和/或再生。因此，研究 RAS 对 VRPC 的影响对于优化 RAS 干预或再生治疗将是重要的。
